WuXi PharmaTech Biotechnology Co., Ltd. has a registered capital of 157,796,566 yuan. It is mainly engaged in the bioassay, process research and development and pilot research of macromolecular drugs. It has a one-stop shop for active intermediates or end products of medicinal biopharmaceuticals. "R&D and pilot testing capabilities.
The company has good basic conditions for product research and development, including research, trial production, and office space of about 15,000 square meters, including a world-class biopharmaceutical research and development and pilot center with a total area of 9000 square meters. In 2015, the company had a total of 550 employees, including 40 doctors and 190 masters. The number of undergraduates and above accounted for about 80%, the national 1,000-person plan talents, the Jiangsu province double-creative talents, and the doctoral program talents. Strictly follow the international advanced standards of the US FDA, European EMEA, China SFDA and other international advanced standards to build a world-class biopharmaceutical research and development, pilot plant, not only to fill the domestic monoclonal antibody market demand, but also to meet the US FDA, EU EMEA and other standards, with Biopharmaceutical research and development capabilities such as monoclonal antibodies that meet international standards.
The company has successively obtained high-tech enterprises in Jiangsu Province, foreign-invested research and development centers in Jiangsu Province, Jiangsu Engineering Technology Research Center, Jiangsu Enterprise Technology Center, Jiangsu Engineering Center, Jiangsu Provincial Postgraduate Workstation, Jiangsu Provincial Key Enterprise R&D Organization, Jiangsu Province Innovation Team, Jiangsu Province Science and Technology Support, Wuxi Oriental Silicon Valley Technology Innovation Team and many other honorary titles.